Predictive Biotech beta launches spine deformity molecular diagnostic test: 4 key points

Salt Lake City-based Predictive Technology Group’s Predictive Biotech beta launched its molecular diagnostic test for spinal deformities, according to Digital Journal.

Advertisement

Here are four key points:

 

1. The diagnostic test is designed to predict spine deformity and syndrome severity.

 

2. The test will initially focus on scoliosis.

 

3. Predictive Biotech is awaiting patent approval of the technology.

 

4. The company plans to collaborate with spine societies to enhance the technology to meet surgeons’ clinical needs.

 

More articles on devices:
St. Jude Medical shares increase 0.32%— 4 notes
Histogenics acquires sole development, marketing rights for NeoCart in Japan: 5 key notes
Study: Cartiva SCI an effective for toe osteoarthritis treatment — 4 points

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.